RE
REVB.US Revelation Biosciences Inc
- Market cap
- USD 2.16M
- P/E
- -
- P/B
- 0.34x
- ROE
- -177.8%
- Dividend yield
- 275,951.08%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is REVB.US undervalued?
Graham numberThe Graham number of Revelation Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Revelation Biosciences Inc fundamental analysis
No fundamental analysis for Revelation Biosciences Inc yet.
Revelation Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of d…
Full company profileRevelation Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Revelation Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.8M | 74.0M | 85.1M | 95.8M | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 45.2M | 70.8M | 81.0M | 90.9M | - | -69.2K | -40.0K | -25.0K | -27.9K | -27.1K | - |
| Operating Income | 18.8M | 32.7M | 38.9M | -3.64K | -145K | -12.0M | -10.9M | -8.66M | -7.98M | -9.07M | -13.5M |
| EBITDA | - | - | - | -3.64K | -145K | -11.9M | -10.8M | -8.63M | -7.95M | -9.04M | -13.0M |
| Net Income | 8.78M | 16.3M | 27.6M | -3.64K | -136K | -12.0M | -10.8M | -120K | -15.0M | -8.91M | -12.9M |
| EPS | - | - | - | -47 | -5,246 | -142,700 | -603 | -59 | -614 | -101 | -23 |
| Balance Sheet | |||||||||||
| Total Assets | 1.89B | 2.10B | 2.46B | 22.7K | 74.2M | 2.04M | 5.50M | 12.2M | 6.62M | 11.6M | 10.0M |
| Total Liabilities | 1.73B | 1.91B | 2.19B | 26.3K | 6.34M | 2.14M | 4.45M | 5.56M | 1.91M | 2.72M | 2.79M |
| Shareholders' Equity | 169M | 188M | 265M | -3.64K | 67.8M | -99.5K | 1.05M | 6.65M | 4.71M | 8.86M | 7.23M |
| Cash & Short-term Investments | 112M | 72.2M | 136M | 147M | 537K | 1.27M | 5.25M | 12.0M | 6.50M | 10.7M | 9.12M |
| Total Debt | - | - | - | - | - | 16.8K | - | - | - | 747K | 805K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.6M | 24.2M | 32.6M | 41.1M | -215K | -11.1M | -11.2M | -7.29M | -18.3M | -8.27M | -10.8M |
| Capital Expenditure | 582K | 804K | 861K | 526K | 4.00 | 132K | 4.00 | 4.00 | 19.2K | 0.00 | 149K |
| Free Cash Flow | - | - | - | - | -215K | -11.2M | -11.2M | -7.29M | -18.3M | -8.27M | -11.0M |
| Ratios | |||||||||||
| ROE | 5.2% | 8.6% | 10.4% | - | -0.2% | - | -1,029.0% | -1.8% | -319.4% | -100.6% | -177.8% |
| ROA | 0.5% | 0.8% | 1.1% | -16.0% | -0.2% | -587.0% | -196.8% | -1.0% | -227.1% | -77.0% | -128.4% |
| Net Profit Margin | 18.0% | 22.0% | 32.5% | 0.0% | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | - | - | - | - | 0.08x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Revelation Biosciences Inc dividends
- Dividend yield
- 275,951.08%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.95B | 67,108 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 7.65M | 426 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:7 on Oct 20, 2026.
Who owns Revelation Biosciences Inc
- Insiders 10.27%
- Institutions 10.24%
- Public & others 79.49%
- Shares outstanding 569K
- Free float 580K
Top funds holding REVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 16.6K | 0.42% | 0.00% | Sep 2026 |
Top institutions holding REVB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sabby Management LLC | 211K | 5.29% | +111.78% | Jun 2026 |
| Citadel Advisors Llc | 38.6K | 0.97% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 17.2K | 0.43% | -60.20% | Jun 2026 |
| HRT FINANCIAL LLC | 17.0K | 0.43% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 13.1K | 0.33% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 6.53K | 0.16% | +60.24% | Jun 2026 |
| Royal Bank of Canada | 747.00 | 0.02% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 344.00 | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 168.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Investment Partners SA | 9.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
Revelation Biosciences Inc company profile
- Company name
- Revelation Biosciences Inc
- Ticker
- REVB.US
- Exchange
- USA Stocks
- Listed since
- Nov 17, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 4660 La Jolla Village Drive, San Diego, CA, United States, 92122
- Phone
- 650 800 3717
- Website
- revbiosciences.com
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences Inc management
4- Mr. James M. RolkeChairman & CEO · born 1969
- Mr. Chester Stanley Zygmont IIICFO & Corporate Secretary · born 1980
- Ms. Sandra VedrickVice President of Human Resources & Investor Relations
- Ms. Carol OdleSenior Director of Clinical Projects